Dr. Garceau serves as a member of the Board of Directors since March 2016. Dr. Garceau has more than 30 years of broad pharmaceutical industry experience. From December 2008 to February 2015 , Dr. Garceau was Executive Vice President and CMO of NPS Pharmaceuticals, Inc. sold to Shire plc in February 2015. From 2002 to December 2008, Dr. Garceau hold several senior leadership positions at Sanofi-Aventis. Previously, Dr. Garceau held various positions, including Vice President of clinical operations, interim head of North American medical and regulatory affairs, and head of U.S. medical research. Prior to Sanofi-Aventis, Dr. Garceau spent 16 years with Pharmacia Corporation. Dr. Garceau is a board-certified pediatrician. He received a bachelor of science in biology from Fairfield University in Fairfield, Connecticut and his doctorate of medicine from the University of Massachusetts Medical School. He is a Fellow of the American Academy of Pediatrics.
Mr. Malca has served as a member of the Board of Directors since 2011. Mr. Malca currently serves as a CEO and Director of D.N.A Biomedical Solutions Ltd., one of our principal shareholders, a position he has held since 2010. Mr. Malca also serves as a director of Arko Holdings Ltd., an Israeli public company. Mr. Malca also serves on the board of directors of a number of private companies, including as chairman of the board of directors of Cardioart Technologies LTD, a medical device company. Mr. Malca received a B.A. and an M.A. from Bar Ilan University.